Genetic Analysis AS (XSAT:GEAN) OCF Yield %: -2.31 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:GEAN Genetic Analysis AS XSAT:GEAN
34 GF Score
Price kr0.66
GF Value kr0.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Genetic Analysis AS OCF Yield %?

Genetic Analysis AS XSAT:GEAN -2.94% 34 OCF Yield % is -2.31 as of Jul. 19, 2026. GuruFocus rates XSAT:GEAN with a GF Score™ of 34/100 and a GF Value™ of kr0.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Genetic Analysis AS ranks worse than 61.97% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Genetic Analysis AS's Trailing 12-Month Cash Flow from Operations is kr-1.05 Mil, and Market Cap is kr45.60 Mil. Therefore, Genetic Analysis AS's OCF Yield % for today is -2.31%.

The historical rank and industry rank for Genetic Analysis AS's OCF Yield % or its related term are showing as below:

XSAT:GEAN' s OCF Yield % Range Over the Past 10 Years
Min: -99.2   Med: -41.82   Max: 7.61
Current: -2.31


During the past 7 years, the highest OCF Yield % of Genetic Analysis AS was 7.61%. The lowest was -99.20%. And the median was -41.82%.

XSAT:GEAN's OCF Yield % is ranked worse than
61.97% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.07 vs XSAT:GEAN: -2.31

Genetic Analysis AS's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Genetic Analysis AS OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Genetic Analysis AS OCF Yield % Related Terms


Genetic Analysis AS OCF Yield % Historical Data

* Premium members only.

The historical data trend for Genetic Analysis AS's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Analysis AS OCF Yield % Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -17.76 -41.10 -53.07 -46.15 4.96

Genetic Analysis AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.19 8.55 -34.75 66.48 -48.41

XSAT:GEAN vs TMO, DHR, IDXX: OCF Yield % Comparison

For the Diagnostics & Research subindustry, Genetic Analysis AS's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS OCF Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's OCF Yield % falls into.


XSAT:GEAN
34GF Score
Genetic Analysis AS XSAT:GEAN
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetic Analysis AS OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Genetic Analysis AS's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=2.401 / 48.3609
=4.96%

Genetic Analysis AS's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-5.017 * 4 / 41.4522
=-48.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -2.31 mean?
Genetic Analysis AS (XSAT:GEAN) has a OCF Yield % of -2.31 as of Jul. 19, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #132 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 62%.
Is Genetic Analysis AS's OCF Yield % too high?
Genetic Analysis AS's current OCF Yield % is -2.31. Based on the distribution chart, Genetic Analysis AS ranks #132 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #132 out of 213 companies for OCF Yield %. This places Genetic Analysis AS in the lower half of its industry. The industry median OCF Yield % is 1.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.07, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current OCF Yield % is -2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current OCF Yield % is -2.31. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current OCF Yield % is -2.31 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued. The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54. GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.

Key valuation signals for XSAT:GEAN:

  • OCF Yield %: -2.31
  • GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genetic Analysis AS Business Description

Other Exchanges 8V8:Germany
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score

Get the complete analysis for XSAT:GEAN

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.66
Price
kr0.54
GF Value